Brain-derived neurotrophic factor: focus on the pathogenesis of multiple myeloma and the development of treatment-induced peripheral neuropathy

References

• Suska A, Jurczyszyn A. Epidemiology and etiopathogenesis of multiple myeloma and monoclonal gammapathy of undetermined significance. Postepy Hig Med Dosw. 2018;72:953–965.
   Web of Science ®Google Scholar
• Jurczyszyn A, Charliński G, Suska A, et al. The importance of cytogenetic and molecular aberrations in multiple myeloma. Acta Haematol Pol. 2021;52:361–370.
   Google Scholar
• Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101–119.
   PubMed Web of Science ®Google Scholar
• Fitzgerald E, Kiely P, Leary HO. Intracranial involvement in multiple myeloma presenting as a cranial nerve palsy. J Hematol. 2019;8(1):29–33.
   PubMedGoogle Scholar
• Olechnowicz SWZ, Weivoda MM, Lwin ST, et al. Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment. Sci Rep. 2019;9(1):14189.
   PubMedGoogle Scholar
• Łuczkowska K, Rogińska D, Kulig P, et al. Bortezomib-induced epigenetic alterations in nerve cells: focus on the mechanisms contributing to the peripheral neuropathy development. Int J Mol Sci. 2022;23(5):2431.
   PubMed Web of Science ®Google Scholar
• Łuczkowska K, Machaliński B. Peripheral neuropathy in patients with multiple myeloma: molecular effects of bortezomib. Acta Haematol Pol. 2021;52:375–381.
   Google Scholar
• Colucci-D’Amato L, Speranza L, Volpicelli F. Neurotrophic factor BDNF physiological functions and therapeutic potential in depression neurodegeneration and brain cancer. Int J Mol Sci. 2020;21(20):7777.
   PubMed Web of Science ®Google Scholar
• Szudy‐Szczyrek A, Mlak R, Bury‐Kamińska M, et al. Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. Br J Haematol. 2020;191(1):77–89.
   PubMed Web of Science ®Google Scholar
• Azoulay D, Horowitz NA. Brain-derived neurotrophic factor in hematological malignancies: from detrimental to potentially beneficial. Blood Rev. 2022;51:100871.
   PubMed Web of Science ®Google Scholar
• Tajbakhsh A, Mokhtari-Zaer A, Rezaee M, et al. Therapeutic potentials of BDNF/TrkB in breast cancer; current status and perspectives. J Cell Biochem. 2017;118(9):2502–2515.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang S, Liu Y, et al. Serum levels of BDNF in patients with adenoma and colorectal cancer. Dis Markers. 2021;2021:8867368.
   PubMed Web of Science ®Google Scholar
• Pius-Sadowska E, Machaliński B. Role of neurotrophins/neurotrophin receptors axis in regulation of neuronal homeostasis. Postepy Biol Komorki. 2014;2:285–314.
   Google Scholar
• Machaliński B, Lażewski-Banaszak P, Dąbkowska E, et al. The role of neurotrophic factors in regeneration of the nervous system. Neurol Neurochir Pol. 2012;46(6):579–590.
   PubMed Web of Science ®Google Scholar
• Adachi N, Numakawa T, Richards M, et al. New insight in expression transport and secretion of brain-derived neurotrophic factor: implications in brain-related diseases. World J Biol Chem. 2014;5(4):409–428.
   PubMedGoogle Scholar
• Zheng F, Zhou X, Luo Y, et al. Regulation of brain-derived neurotrophic factor exon IV transcription through calcium responsive elements in cortical neurons. PLOS One. 2011;6(12):e28441.
   PubMed Web of Science ®Google Scholar
• Tao X, West AE, Chen WG, et al. A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF. Neuron. 2002;33(3):383–395.
   PubMed Web of Science ®Google Scholar
• Zheng F, Zhou X, Moon C, et al. Regulation of brain-derived neurotrophic factor expression in neurons. Int J Physiol Pathophysiol Pharmacol. 2012;4(4):188–200.
   PubMedGoogle Scholar
• Koyama Y, Tsujikawa K, Matsuda T, et al. Endothelin increases expression of exon III- and exon IV-containing brain-derived neurotrophic factor transcripts in cultured astrocytes and rat brain. J Neurosci Res. 2005;80(6):809–816.
   PubMed Web of Science ®Google Scholar
• Nair B, Wong-Riley MTT. Transcriptional regulation of brain-derived neurotrophic factor coding exon IX. J Biol Chem. 2016;291(43):22583–22593.
   PubMed Web of Science ®Google Scholar
• Vargas MR, Pehar M, Cassina P, et al. Stimulation of nerve growth factor expression in astrocytes by peroxynitrite. In Vivo. 2004;18(3):269–274.
   PubMed Web of Science ®Google Scholar
• Mousavi K, Jasmin BJ. BDNF is expressed in skeletal muscle satellite cells and inhibits myogenic differentiation. J Neurosci. 2006;26(21):5739–5749.
   PubMed Web of Science ®Google Scholar
• Grasman JM, Kaplan DL. Human endothelial cells secrete neurotropic factors to direct axonal growth of peripheral nerves. Sci Rep. 2017;7(1):4092.
   PubMedGoogle Scholar
• Nakahashi T, Fujimura H, Altar CA, et al. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett. 2000;470(2):113–117.
   PubMed Web of Science ®Google Scholar
• Nockher WA, Renz H. Neurotrophins in clinical diagnostics: pathophysiology and laboratory investigation. Clin Chim Acta. 2005;352(1–2):49–74.
   PubMed Web of Science ®Google Scholar
• Lessmann V, Brigadski T. Mechanisms locations and kinetics of synaptic BDNF secretion: an update. Neurosci Res. 2009;65(1):11–22.
   PubMed Web of Science ®Google Scholar
• Dechant G, Neumann H. Neurotrophins. Adv Exp Med Biol. 2002;513:303–334.
   PubMed Web of Science ®Google Scholar
• Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736.
   PubMed Web of Science ®Google Scholar
• Hoshi H, McKeehan WL. Production of an auto-stimulatory growth factor by human hepatoma cells abrogates requirement for a brain-derived factor. In Vitro Cell Dev Biol. 1985;21(2):125–128.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Wada RK, Yamashiro JM, et al. Expression of brain-derived neurotrophic factor and p145TrkB affects survival differentiation and invasiveness of human neuroblastoma cells. Cancer Res. 1995;55(8):1798–1806.
   PubMed Web of Science ®Google Scholar
• Marchetti D, McCutcheon I, Ross M, et al. Inverse expression of neurotrophins and neurotrophin receptors at the invasion front of human-melanoma brain metastases. Int J Oncol. 1995;7(1):87–94.
   PubMed Web of Science ®Google Scholar
• Yin B, Ma ZY, Zhou ZW, et al. The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model. Oncogene. 2015;34(6):761–770.
   PubMed Web of Science ®Google Scholar
• Zhang S, Hui LP, Li CY, et al. More expression of BDNF associates with lung squamous cell carcinoma and is critical to the proliferation and invasion of lung cancer cells. BMC Cancer. 2016;16:171.
   PubMed Web of Science ®Google Scholar
• Radin DP, Patel P. BDNF: an oncogene or tumor suppressor? Anticancer Res. 2017;37(8):3983–3990.
   PubMed Web of Science ®Google Scholar
• Pearse RN, Swendeman SL, Li Y, et al. A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood. 2005;105(11):4429–4436.
   PubMed Web of Science ®Google Scholar
• Sun CY, Hu Y, Huang J, et al. Brain-derived neurotrophic factor induces proliferation migration and VEGF secretion in human multiple myeloma cells via activation of MEK-ERK and PI3K/AKT signaling. Tumour Biol. 2010;31(2):121–128.
   PubMedGoogle Scholar
• Zhang L, Hu Y, Sun CY, et al. Lentiviral shRNA silencing of BDNF inhibits in vivo multiple myeloma growth and angiogenesis via down-regulated stroma-derived VEGF expression in the bone marrow milieu. Cancer Sci. 2010;101(5):1117–1124.
   PubMed Web of Science ®Google Scholar
• Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12(1):9–18.
   PubMed Web of Science ®Google Scholar
• Hu Y, Sun CY, Wang HF, et al. Brain-derived neurotrophic factor promotes growth and migration of multiple myeloma cells. Cancer Genet Cytogenet. 2006;169(1):12–20.
   PubMedGoogle Scholar
• Chu M, Fan Y, Wu L, et al. Knockdown of lncRNA BDNF-AS inhibited the progression of multiple myeloma by targeting the miR-125a/b-5p-BCL2 axis. Immun Ageing. 2022;19(1):3.
   PubMed Web of Science ®Google Scholar
• Chu ZB, Sun CY, Yang D, et al. Role of brain-derived neurotrophic factor in bone marrow angiogenesis in multiple myeloma. J Huazhong Univ Sci Technolog Med Sci. 2013;33(4):485–490.
   PubMedGoogle Scholar
• Hu Y, Wang YD, Guo T, et al. Identification of brain-derived neurotrophic factor as a novel angiogenic protein in multiple myeloma. Cancer Genet Cytogenet. 2007;178(1):1–10.
   PubMedGoogle Scholar
• Wang YD, Hu Y, Huang J, et al. Antitumor effect of anti-brain derived neurotrophic factor monoclonal antibody in human multiple myeloma xenograft animal model. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16(5):1069–1072.
   PubMedGoogle Scholar
• Ai LS, Sun CY, Zhang L, et al. Inhibition of BDNF in multiple myeloma blocks osteoclastogenesis via down-regulated stroma-derived RANKL expression both in vitro and in vivo. PLOS One. 2012;7(10):e46287.
   PubMed Web of Science ®Google Scholar
• Sun CY, Chu ZB, She XM, et al. Brain-derived neurotrophic factor is a potential osteoclast stimulating factor in multiple myeloma. Int J Cancer. 2012;130(4):827–836.
   PubMed Web of Science ®Google Scholar
• Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95(2):311–319.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127(2):165–172.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed refractory myeloma. N Engl J Med. 2003;348(26):2609–2617.
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24(27):4507–4514.
   PubMed Web of Science ®Google Scholar
• Łuczkowska K, Taryma-Leśniak O, Bińkowski J, et al. Long-term treatment with bortezomib induces specific methylation changes in differentiated neuronal cells. Cancers. 2022;14(14):3402.
   PubMed Web of Science ®Google Scholar
• Sikandar S, Minett MS, Millet Q, et al. Brain-derived neurotrophic factor derived from sensory neurons plays a critical role in chronic pain. Brain. 2018;141(4):1028–1039.
   PubMedGoogle Scholar
• Palanca A, Casafont I, Berciano MT, et al. Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons. Cell Mol Life Sci. 2014;71(10):1961–1975.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu X, Zhang T, et al. Cytoprotective effects of proteasome beta5 subunit overexpression in lens epithelial cells. Mol Vis. 2007;13:31–38.
   PubMed Web of Science ®Google Scholar
• Azoulay D, Lavie D, Horowitz N, et al. Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma. Br J Haematol. 2014;164(3):454–456.
   PubMed Web of Science ®Google Scholar
• Azoulay D, Giryes S, Nasser R, et al. Prediction of chemotherapy-Induced peripheral neuropathy in patients with lymphoma and myeloma: the roles of brain-derived neurotropic factor protein levels and a gene polymorphism. J Clin Neurol. 2019;15(4):511–516.
   PubMed Web of Science ®Google Scholar